Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone
<p>Abstract</p> <p>Background</p> <p>The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is a randomized, double-blind, active-controlled trial designed to compare the rate of coronary heart disease events in high-risk hypertensive p...
Main Authors: | Leenen Frans HH, Williamson Jeff D, Wright Jackson T, Cushman William C, Cutler Jeffrey A, Davis Barry R, Piller Linda B, Einhorn Paula T, Randall Otelio S, Golden John S, Haywood L Julian |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2002-11-01
|
Series: | Current Controlled Trials in Cardiovascular Medicine |
Subjects: | |
Online Access: | http://cvm.controlled-trials.com/content/3/1/10 |
Similar Items
-
Comments on ALLHAT and doxazosin
by: Krakoff Lawrence R
Published: (2001-11-01) -
A new era in hypertension research: discussing the findings of ALLHAT
by: Furberg Curt D
Published: (2001-11-01) -
Chlorthalidone, not hydrochlorothiazide, is the right diuretic for comparison
by: Ravi Tejraj Mehta, et al.
Published: (2018-03-01) -
Antihypertensive efficacy of metoprolol XL/Low dose chlorthalidone (6.25 mg) combination: a randomized, comparative study in Indian patients with mild-to-moderate essential hypertension
by: Pareek A, et al.
Published: (2009-07-01) -
Combining angiotensin receptor blockers with chlorthalidone or hydrochlorothiazide – which is the better alternative? A meta-analysis
by: Elena Filipova, et al.
Published: (2020-08-01)